July 25-27 2017

San Diego, CA

 

Day One
Wednesday July 26th, 2017

Day Two
Thursday July 27th, 2017

08.00
Coffee & Registration

09.00
Chairman’s Opening Remarks

Clinical Development of Innate Killer Cell Therapies

09.10
Next-Generation Immune Cell Engagers for Tumor-Targeting of Innate Immunity

Synopsis

  • Affimed develops tetravalent, bispecific immuno-engagers for tumor-targeting of T-cells and NK-cells based on proprietary scaffolds and engager domains
  • Evaluate the potency and efficacy of several immuno-engagers currently in clinical mono and combination trials
  • Learn about recent developments from our NK-cell engager platform demonstrating superior efficacy over conventional Fc-based approaches

09.40
Immune Responses and Clinical Outcomes in the Clinical Trials with Random Donor Derived Expanded NK Cell

  • Hwang Yu-Kyeong Director, Institute of Cell Therapy , Green Cross LabCell

Synopsis

  • Discuss the safety of random donor derived expansion NK cell
  • Assess immune activation by allogeneic NK cell infusion: How can we control the rejection and antibody induction?
  • Explore how NK cell persistency and efficacy can control by pre-treatment regimen
  • Discuss key considering factors in NK cell treatment: KIR-ligand mismatch and donor selection criteria
  • Consider thedifferences of NK cell and T cell therapy in GvHD/GvT aspect
  • Debate what is the most ideal indication of allogeneic NK cell therapy

10.10
Morning Refreshments & Networking

11.10
Off the Shelf Engineered NK Cells Based on the NK-92 Platform

Synopsis

  • Update on clinical trial activities with aNK
  • Explore how haNK cells express the high affinity Fc-Receptor for combination therapy with mAbs
  • Learn how taNK cells are engineered to express CARs for neo-epitopes
  • Analyze how to Augment NK activity with IL-15 super-agonist Altor 803
  • Review optimizing NK target activity through CRISR based gene manipulation

11.40
Placental Natural Killer Cells (PNK-007) for the Treatment of Hematologic Malignancies

Synopsis

  • Review clinical studies suggest that adoptive transfer of allogeneic natural killer cells represent a promising treatment for patients with hematological malignancies and solid tumors
  • Discover how Celgene Cellular Therapeutics has established a cultivation process to generate human NK cells (PNK-007) from umbilical cord blood CD34+ cells with substantial cytolytic activity against several human tumor cell lines, primary AML and primary multiple myeloma cells
  • Discuss two Phase 1 clinical studies of PNK-007 infusion, one in AML and the other in multipel myeloma, will be discussed

12.10
Lunch & Networking

Ensuring GMP Compliance for Cell Culture

13.40
Strategies for Processing of NK Cells Ex Vivo for Cancer Immunotherapy

  • Markus Granzin Scientist, Clinical Research, Process Development, Miltenyi Biotec

Synopsis

  • Explore options for standardized large scale separation of NK cells applicable in the clinic
  • Introduce a closed system for cultivation of innate killer cells in a fully automated way
  • Identify an optimal culture medium for NK cells
  • Explain how to expand primary human NK cells to high numbers based on feeder cells and cytokines

14.40
Cancer Immunotherapy with Ex Vivo-Generated NK Cells from Hematopoietic Progenitor Cells

  • Harry Dolstra Associate Professor Translational ImmunoHematology., RadboudUMC

Synopsis

  • Demonstrate reliable, scalable and GMP-compliant culture methods for the ex vivo generation of highly active NK cells products under feeder-free conditions, and practically devoid of allogeneic T cell contamination reducing GVHD risks
  • Determine feasibility, safety and biological properties of “First generation” allogeneic HSPC-NK cell infusion following lymphodepleting chemotherapy in older AML patients
  • Explain that “Second generation” products exploiting the AhR antagonist SR1 and the combination of IL-15 and IL-12 generates superior HSPC-NK cells with enhanced antitumor properties
  • Discuss first pre-clinical results of maximizing the anti-tumor effect of “Second generation” HSPC-NK cells in combination with immune modulating agents in AML and Ovarian cancer model systems

14.40
hnCD16-NK Cells: Off-the-Shelf Cornerstone Approach for Solid Tumors

Synopsis

  • Pluripotent cell technology represents a powerful approach to make cell-based immunotherapies available to a wide range of patients through the generation of a consistent and renewable “off-the-shelf” source of cellular therapeutics
  • To address the need for advanced and combinatorial cancer therapies, we developed a unique and effective strategy to create a renewable source of genetically engineered “off-the-shelf” NK cells with augmented function, including enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and persistence
  • Through targeted transgene integration, learn how we produced a clonal pluripotent cell master cell line to continuously produce NK cells engineered to uniformly express a novel high affinity, non-cleavable version of CD16 Fc receptor (hnCD16-NK)
  • Discover how preclinical data highlighted the therapeutic value of hnCD16-NK cells as an ideal ADCC-mediated “off-the-shelf” NK cell-based immunotherapeutic product with augmented persistence, anti-tumor capacity, manufacturing reliability and preclinical efficacy

15.10
Overcoming Practical Barriers to Adoptive Immunotherapy with Expanded NK Cells

  • Dean Lee Associate Professor, VP & Co-Founder, Nationwide Children’s Hospital & Cyto-Sen Therapeutics

Synopsis

  • Description of clinical IL-21 expansion platform
  • Pros, cons, and solutions for cryopreservation
  • Preclinical models
  • Clinical applications- safety and efficacy
  • Correlative findings- hyperfunctional subsets and crosstalk with adaptive immunit

15.40
Afternoon Refreshments & Networking

16.10
PANEL: The Future of Innate Killer Cell Therapy

  • Bob Valamehr VP, Cancer , Immunotherapy Fate Therapeutics
  • Xiaokui Zhang Senior Director, Research & Development, Celgene
  • Hans Klingemann VP, R&D , NantKWest
  • Mike Caligiuri Director & CEO , Ohio State University Comprehensive Cancer Center & Ohio State’s Hospital
  • Evren Alici Assistant Professor, Gene & Cell Therapy Group , Karolinska Institutet

Synopsis

  • Where Next: What lessons are can we take from CAR-T success and failures?
  • How can we harnessing the benefits of Innate Killer cells for solid tumor indications
  • What are the novel strategies to manipulate innate killer cells to be better killers?
  • Might the innate killer therapies have a potential impact beyond oncology indications?
  • Comparison of innate killer therapies to other immune-oncology drug candidates?
  • What are the potential obstacles innate killer therapies need to overcome to ensure success?

17.10
Chairman’s Closing Remarks

17.15
Close of Summit